Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul

Executive Summary

BsUFA revenue amounts and fees will be separated from PDUFA and relative contribution of each fee type to the overall pot will change; user fee revenue target for program's first year is $45m.


Related Content

Biosimilar User Fee Forecast: Unchanged Or Lower In FY 2019, US FDA Says
User Fees For FY 2017 Make Sponsors Happy, Manufacturers Sad
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure
Biosimilar User Fee Collections Rise, But Little Spent On Program Costs
Biosimilars Reviews Could Be Extended Two Months In BsUFA II
Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself
Pending Biosimilars
Biosimilars Program Could 'Explode,' Woodcock Warns Congress
Biosimilar User Fees Could Be Raised Significantly In Renewal Talks


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts